Skip to main content
Quest Diagnostics

Cerebrospinal Fluid Aβ42, Total Tau, and Phosphorylated Tau in the Evaluation of Alzheimer’s Dementia: Experience From a Commercial Reference Laboratory

4th edition of Innovations and State of the Art in Alzheimer's & Dementia

ISAD 2023

Barcelona, Spain, Sep 13-14 , 2023

Oral presentation: Cerebrospinal Fluid Aβ42, Total Tau, and Phosphorylated Tau in the Evaluation of Alzheimer’s Dementia: Experience From a Commercial Reference Laboratory

Authors: Batish SD, Haji-Sheikhi F, Kare AR, Datta V, Meservey M, Radcliff J

Specialty: Neurology

Related content

On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
On-Demand Webinar
The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease
Conference Presentation
The AlzMatch Study: remote plasma acquisition to pre-screen for preclinical Alzheimer's disease trials
Conference Presentation
Cerebrospinal Fluid Aβ42, Total Tau, and Phosphorylated Tau in the Evaluation of Alzheimer’s Dementia: Experience From a Commercial Reference Laboratory

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.